We are live on
!
Find out more
ASA
Armstrong Shaw Associates Portfolio holdings
AUM
$95.2M
1-Year Est. Return
23.67%
This Fund
S&P 500
This Quarter
Est. Return
+5.23%
1 Year Est. Return
+23.67%
3 Year Est. Return
+51.2%
5 Year Est. Return
+82.8%
10 Year Est. Return
+225.63%
AUM
$553M
AUM Growth
-$261M
(-32%)
Cap. Flow
-$290M
Cap. Flow
% of AUM
-52.4%
Top 10 Holdings %
Top 10 Hldgs %
37.82%
Holding
44
New
1
Increased
1
Reduced
36
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NOV
NOV
|
+$5.51M |
| 2 |
DuPont de Nemours
DD
|
+$184K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$16.4M |
| 2 |
UnitedHealth
UNH
|
+$13.2M |
| 3 |
MetLife
MET
|
+$12.9M |
| 4 |
CMCSK
COMCAST CORP SPL A (NEW)
CMCSK
|
+$12.7M |
| 5 |
CVS Health
CVS
|
+$12.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.54% |
| 2 | Healthcare | 19.29% |
| 3 | Technology | 14.63% |
| 4 | Consumer Discretionary | 11.03% |
| 5 | Energy | 9.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Oracle
ORCL
$331B
| $11.9M | 2.16% |
294,404
-156,148
| -35% | -$6.42M |
|
27
Amgen
AMGN
$203B
| $11.3M | 2.05% |
95,676
-55,198
| -37% | -$6.39M |
|
|
28
UnitedHealth
UNH
$382B
| $11.2M | 2.03% |
137,106
-167,192
| -55% | -$13.2M |
|
29
AbbVie
ABBV
$458B
| $11.2M | 2.02% |
198,306
-111,792
| -36% | -$5.86M |
|
|
COV
30
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $10.9M | 1.97% |
121,069
-219,384
| -64% | -$16.4M |
|
31
GE Aerospace
GE
$367B
| $10.7M | 1.94% |
85,300
-46,597
| -35% | -$5.93M |
|
32
Chevron
CVX
$388B
| $10.3M | 1.86% |
78,849
-42,734
| -35% | -$5.32M |
|
|
ESRX
33
DELISTED
Express Scripts Holding Company
ESRX
| $8.91M | 1.61% |
128,521
-90,208
| -41% | -$6.35M |
|
|
PX
34
DELISTED
Praxair Inc
PX
| $8.11M | 1.47% |
61,021
-33,572
| -35% | -$4.4M |
|
|
WBC
35
DELISTED
WABCO HOLDINGS INC.
WBC
| $6.15M | 1.11% |
57,604
-42,093
| -42% | -$4.51M |
|
|
36
NOV
NOV
$7.45B
| $6.09M | 1.1% |
+73,966
| New | +$5.51M |
|
37
Berkshire Hathaway Class A
BRK.A
$1.07T
| $3.8M | 0.69% |
20
| – | – |
|
38
Verizon
VZ
$194B
| $2.27M | 0.41% |
46,400
-1,270
| -3% | -$61.5K |
|
39
Apple
AAPL
$4.89T
| $485K | 0.09% |
20,860
-280
| -1% | -$5.96K |
|
40
Nuveen Select Tax-Free Income Portfolio
NXP
$900M
| $282K | 0.05% |
20,000
| – | – |
|
|
NIO
41
DELISTED
NUVEEN MUNICIPAL OPPORTUNITY FUND INC
NIO
| $268K | 0.05% |
19,000
| – | – |
|
42
Ameriprise Financial
AMP
$46.8B
| $242K | 0.04% |
2,020
| – | – |
|
43
BlackRock MuniYield Quality Fund III
MYI
$709M
| – | – |
-20,000
| Closed | -$272K |
|
|
ADT
44
DELISTED
ADT Corp
ADT
| – | – |
-370,539
| Closed | -$11.1M |
|
Similar funds
AEPLI
GG
VI
TAM
WCM
QT
OC
KC
Armstrong Shaw Associates's Q2 2014 Portfolio in Review
As of Q2 2014, Armstrong Shaw Associates held 44 positions worth $553M, down 32% from $814M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Armstrong Shaw Associates withdrew a net $290M in Q2 2014, closing 2 positions and reducing 36 holdings. Its most notable exit was ADT Corp, an estimated $11.1M position sold in full.
By sector, the portfolio is most concentrated in Financials at 24% of assets, down from 24% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Armstrong Shaw Associates opened a new position in NOV worth $6.09M.
- Armstrong Shaw Associates's largest Q2 2014 buy was NOV: 73,966 shares worth $6.09M.
- Armstrong Shaw Associates added most to DuPont de Nemours in Q2 2014, an estimated $184K increase.
- Armstrong Shaw Associates's biggest Q2 2014 reduction was COVIDIEN PLC COM SHS NEW (IRELAND), cutting an estimated $16.4M.
- Armstrong Shaw Associates fully exited ADT Corp in Q2 2014, selling an estimated $11.1M.
- Armstrong Shaw Associates's ten largest holdings make up 38% of its $553M portfolio in Q2 2014.
- Armstrong Shaw Associates opened 1 new position and closed 2 in Q2 2014.
- Armstrong Shaw Associates's portfolio value fell 32% quarter-over-quarter to $553M.
Based on Armstrong Shaw Associates's 13F filing for Q2 2014, filed 18 Jul 2014.